Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have earned an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $30.00.

Several equities analysts have commented on KYTX shares. Wall Street Zen downgraded Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Wednesday, June 24th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Kyverna Therapeutics in a report on Wednesday, June 3rd.

Institutional Investors Weigh In On Kyverna Therapeutics

A number of hedge funds have recently bought and sold shares of the company. AIGH Capital Management LLC grew its position in Kyverna Therapeutics by 33.3% in the 1st quarter. AIGH Capital Management LLC now owns 2,000,000 shares of the company’s stock worth $17,260,000 after purchasing an additional 500,000 shares during the last quarter. Walleye Capital LLC bought a new position in shares of Kyverna Therapeutics during the 2nd quarter worth about $2,188,000. Renaissance Technologies LLC raised its position in shares of Kyverna Therapeutics by 106.6% during the first quarter. Renaissance Technologies LLC now owns 367,492 shares of the company’s stock valued at $3,171,000 after buying an additional 189,593 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Kyverna Therapeutics during the second quarter valued at about $27,931,000. Finally, Maven Securities LTD bought a new stake in shares of Kyverna Therapeutics in the fourth quarter valued at about $1,376,000. 18.08% of the stock is currently owned by institutional investors.

Kyverna Therapeutics Price Performance

Shares of NASDAQ:KYTX opened at $7.26 on Tuesday. The stock has a market capitalization of $448.96 million, a P/E ratio of -2.47 and a beta of 1.98. The business has a 50-day moving average of $8.09 and a two-hundred day moving average of $8.49. Kyverna Therapeutics has a fifty-two week low of $3.78 and a fifty-two week high of $13.67. The company has a debt-to-equity ratio of 0.15, a current ratio of 9.06 and a quick ratio of 9.06.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.05. On average, equities research analysts predict that Kyverna Therapeutics will post -2.7 EPS for the current fiscal year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical?stage biotechnology company dedicated to developing engineered regulatory T?cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen?specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.